Scandion Oncology A/S
Scandion Oncology develops SCO-101, a novel add-on drug that enhances the effectiveness of established anti-cancer agents. SCO-101 acts as a dual-acting compound, inhibiting drug efflux pump ABCG2 and the liver enzyme UGT1A1, thereby increasing the intracellular concentration of chemotherapy drugs and prolonging their plasma exposure. The company's mission is to potentiate cancer treatments through innovative combination therapies.
Industries
Nr. of Employees
small (1-50)
Scandion Oncology A/S
Københoved, Syddanmark, Denmark, Europe
Patents
4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
US-10975079-B2
View Details4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances
US-9790225-B2
View Details
4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
US-10975079-B2
View Details4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances
US-9790225-B2
View DetailsProducts
Investigational small-molecule oncology add-on agent
An investigational small-molecule agent with a dual mechanism: inhibition of the ABCG2 drug efflux transporter and inhibition of the hepatic enzyme UGT1A1, intended for use in combination with cytotoxic chemotherapy to increase intracellular chemotherapy concentrations and alter systemic exposure of active metabolites.
Investigational small-molecule oncology add-on agent
An investigational small-molecule agent with a dual mechanism: inhibition of the ABCG2 drug efflux transporter and inhibition of the hepatic enzyme UGT1A1, intended for use in combination with cytotoxic chemotherapy to increase intracellular chemotherapy concentrations and alter systemic exposure of active metabolites.
Expertise Areas
- Oncology drug development
- Combination therapy development
- Drug metabolism and pharmacokinetics (DMPK)
- ABC transporter biology (ABCG2-focused)
Key Technologies
- ABC transporter inhibition (ABCG2)
- UGT1A1 inhibition
- Pharmacokinetic modulation
- Small-molecule oncology therapeutics
News & Updates
SCO-101 is a potent inhibitor of ABCG2 and UGT1A1, increasing intracellular concentration of chemotherapy drugs and prolonging their plasma half-life, thereby improving cancer treatment outcomes.
SCO-101 is a potent inhibitor of ABCG2 and UGT1A1, increasing intracellular concentration of chemotherapy drugs and prolonging their plasma half-life, thereby improving cancer treatment outcomes.